The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2025
Synopsis
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The global Chemotherapy-induced Nausea and Vomiting Drugs market was valued at US$ 1689.4 million in 2023 and is anticipated to reach US$ 2358.3 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-induced Nausea and Vomiting Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-induced Nausea and Vomiting Drugs.
Report Scope
The Chemotherapy-induced Nausea and Vomiting Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chemotherapy-induced Nausea and Vomiting Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The global Chemotherapy-induced Nausea and Vomiting Drugs market was valued at US$ 1689.4 million in 2023 and is anticipated to reach US$ 2358.3 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-induced Nausea and Vomiting Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-induced Nausea and Vomiting Drugs.
Report Scope
The Chemotherapy-induced Nausea and Vomiting Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chemotherapy-induced Nausea and Vomiting Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy-induced Nausea and Vomiting Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chemotherapy-induced Nausea and Vomiting Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Chemotherapy-induced Nausea and Vomiting Drugs Market Overview
1.1 Product Overview and Scope of Chemotherapy-induced Nausea and Vomiting Drugs
1.2 Chemotherapy-induced Nausea and Vomiting Drugs Segment by Type
1.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Value Comparison by Type (2024-2030)
1.2.2 5-HT3 Inhibitors
1.2.3 NK1 Inhibitors
1.2.4 Other
1.3 Chemotherapy-induced Nausea and Vomiting Drugs Segment by Application
1.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Value by Application: (2024-2030)
1.3.2 Highly Emetogenic Chemotherapy
1.3.3 Moderately Emetogenic Chemotherapy
1.3.4 Low Emetogenic Chemotherapy
1.3.5 Other
1.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Estimates and Forecasts
1.4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue 2019-2030
1.4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales 2019-2030
1.4.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Chemotherapy-induced Nausea and Vomiting Drugs Market Competition by Manufacturers
2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chemotherapy-induced Nausea and Vomiting Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chemotherapy-induced Nausea and Vomiting Drugs, Product Type & Application
2.7 Chemotherapy-induced Nausea and Vomiting Drugs Market Competitive Situation and Trends
2.7.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chemotherapy-induced Nausea and Vomiting Drugs Players Market Share by Revenue
2.7.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chemotherapy-induced Nausea and Vomiting Drugs Retrospective Market Scenario by Region
3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2019-2030
3.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2019-2024
3.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2025-2030
3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region: 2019-2030
3.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region: 2019-2024
3.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Region: 2025-2030
3.4 North America Chemotherapy-induced Nausea and Vomiting Drugs Market Facts & Figures by Country
3.4.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2019-2030)
3.4.3 North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Chemotherapy-induced Nausea and Vomiting Drugs Market Facts & Figures by Country
3.5.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2019-2030)
3.5.3 Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Indonesia
3.6.10 Thailand
3.6.11 Malaysia
3.6.12 Philippines
3.6.13 Vietnam
3.7 Latin America Chemotherapy-induced Nausea and Vomiting Drugs Market Facts & Figures by Country
3.7.1 Latin America Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2019-2030)
3.7.3 Latin America Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2019-2030)
4.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2019-2024)
4.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Type (2025-2030)
4.1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Type (2019-2030)
4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2019-2030)
4.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2019-2024)
4.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Type (2025-2030)
4.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2019-2030)
5.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2019-2024)
5.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Application (2025-2030)
5.1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Application (2019-2030)
5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2019-2030)
5.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2019-2024)
5.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Application (2025-2030)
5.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Corporation Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Mundipharma
6.3.1 Mundipharma Corporation Information
6.3.2 Mundipharma Description and Business Overview
6.3.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.3.5 Mundipharma Recent Developments/Updates
6.4 Qilu Pharma
6.4.1 Qilu Pharma Corporation Information
6.4.2 Qilu Pharma Description and Business Overview
6.4.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.4.5 Qilu Pharma Recent Developments/Updates
6.5 Teva
6.5.1 Teva Corporation Information
6.5.2 Teva Description and Business Overview
6.5.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.5.5 Teva Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Heron Therapeutics
6.6.1 Heron Therapeutics Corporation Information
6.6.2 Heron Therapeutics Description and Business Overview
6.6.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.7.5 Heron Therapeutics Recent Developments/Updates
6.8 Roche
6.8.1 Roche Corporation Information
6.8.2 Roche Description and Business Overview
6.8.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.8.5 Roche Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Tesaro
6.10.1 Tesaro Corporation Information
6.10.2 Tesaro Description and Business Overview
6.10.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
6.10.5 Tesaro Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chemotherapy-induced Nausea and Vomiting Drugs Industry Chain Analysis
7.2 Chemotherapy-induced Nausea and Vomiting Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chemotherapy-induced Nausea and Vomiting Drugs Production Mode & Process
7.4 Chemotherapy-induced Nausea and Vomiting Drugs Sales and Marketing
7.4.1 Chemotherapy-induced Nausea and Vomiting Drugs Sales Channels
7.4.2 Chemotherapy-induced Nausea and Vomiting Drugs Distributors
7.5 Chemotherapy-induced Nausea and Vomiting Drugs Customers
8 Chemotherapy-induced Nausea and Vomiting Drugs Market Dynamics
8.1 Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends
8.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Drivers
8.3 Chemotherapy-induced Nausea and Vomiting Drugs Market Challenges
8.4 Chemotherapy-induced Nausea and Vomiting Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
